



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |           |  |
|---|-----------|--|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>A61K 39/00, 39/38, 39/02, C12N 15/64</b>   | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 99/47165</b><br><b>(43) International Publication Date:</b> 23 September 1999 (23.09.99)   |
| <b>(21) International Application Number:</b> PCT/US99/05625<br><b>(22) International Filing Date:</b> 17 March 1999 (17.03.99)<br><b>(30) Priority Data:</b><br>09/044,065                      18 March 1998 (18.03.98)                      US<br><b>(71) Applicants:</b> THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND [US/US]; 1430 Tulane Avenue, New Orleans, LA 70112 (US). SMITHKLINE BEECHAM [GB/GB]; SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).<br><b>(72) Inventors:</b> CLEMENTS, John, D.; 7900 Jeanette Place, New Orleans, LA 70118 (US). FRIEDE, Martin; Rue de l'Institut 89, B-1330 Rixensart (BE).<br><b>(74) Agents:</b> BALDWIN, Geraldine, F. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US). |           | <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| <b>(54) Title:</b> PRODUCTION OF PURIFIED MUTANT ENTEROTOXIN FOR USE AS AN ADJUVANT   |           |  |
| <b>(57) Abstract</b><br><br>The present invention is directed towards compositions and methods which provide a genetically distinct mutant of <i>E. coli</i> heat-labile enterotoxin (LT). Specifically, the invention relates to formulations and methods for use of a mutant LT designated LT (R192G) which is shown to have adjuvant activity without the toxicity associated with wild type LT, said mutant holotoxin being provided in pure form, substantially free of excess B-subunit. The LR(R192G) is useful when combined with free B-subunit to induce an immune response.  |           |  |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |  | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali   | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 |    |  | PL | Poland                                       |    |                          |
| CN | China                    | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CU | Cuba                     | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DK | Denmark                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| EE | Estonia                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |

**PRODUCTION OF PURIFIED MUTANT ENTEROTOXIN  
FOR USE AS AN ADJUVANT**

---

**1. FIELD OF THE INVENTION**

The present invention is directed towards  
5 compositions and methods which provide a genetically distinct  
mutant of *E. coli* heat-labile enterotoxin (LT).  
Specifically, the invention relates to formulations and  
methods for use of a mutant LT designated LT(R192G), modified  
by a single amino acid substitution that substantially  
10 reduces its inherent toxicity but leaves intact the adjuvant  
properties of the molecule, provided as a single mutant A-  
subunit with five B-subunits, i.e., mutant holotoxin, which  
is shown to have adjuvanticity without the toxicity  
associated with wild type LT, said mutant holotoxin being  
15 provided in pure form, free of excess B-subunit.

**2. BACKGROUND OF THE INVENTION**

The World Health Organization report of Infectious  
Disease deaths for 1995 indicated that there were more than  
13 million deaths world-wide during that year. The majority  
20 of those deaths were caused by organisms that first make  
contact with and then either colonize or cross mucosal  
surfaces to infect the host. The overall morbidity caused by  
these organisms and other pathogens that interact with  
mucosal surfaces is impossible to calculate.

25 Traditional vaccine strategies that involve  
parenteral immunization with inactivated viruses or bacteria  
or subunits of relevant virulence determinants of those  
pathogens do not prevent those interactions. In fact,  
traditional vaccine strategies do not prevent infection but  
30 instead resolve infection before disease ensues. In some  
cases, HIV for example, once the virus crosses the mucosal  
surface and enters the host cell, be that a dendritic cell,

an epithelial cell, or a T-cell, the host-parasite relationship is moved decidedly in favor of the parasite (HIV). In that case, as in many others, a vaccine strategy that does not prevent the initial infection of the host is  
5 unlikely to succeed.

Recently, a great deal of attention has focused on mucosal immunization as a means of inducing secretory IgA (sIgA) antibodies directed against specific pathogens of mucosal surfaces. The rationale for this is the recognition  
10 that sIgA constitutes greater than 80% of all antibodies produced in mucosal-associated lymphoid tissues in humans and that sIgA may block attachment of bacteria and viruses, neutralize bacterial toxins, and even inactivate invading viruses inside of epithelial cells. In addition, the existence of a Common Mucosal Immune System permits  
15 immunization on or at one mucosal surface to induce secretion of antigen-specific sIgA at distant mucosal sites. It is only now being appreciated that mucosal immunization may be an effective means of inducing not only sIgA but also systemic antibody and cell-mediated immunity.

20 The mucosal immune response can be divided into two phases (McGhee and Kiyono, 1993, *Infect Agents Dis* 12:55-73). First, the inductive phase involves antigen presentation and the initiation events which dictate the subsequent immune response. During the initiation events, antigen-specific lymphocytes are primed and migrate from the inductive sites  
25 (e.g., Peyer's patches in the enteric mucosa) through the regional lymph nodes, into the circulation and back to mucosal effector sites (e.g., lamina propria). Once these effector cells have seeded their effector sites, the second phase, or effector phase, of the mucosal immune response can  
30 occur. A significant difference between mucosal immunization and parenteral immunization is that both mucosal and systemic immunity can be induced by mucosal immunization while

parenteral immunization generally results only in systemic responses.

Most studies conducted to date have dealt with the secretory antibody component of the mucosal response and the complex regulatory issues involved with induction of sIgA following mucosal immunization and not with the systemic antibody response or cellular immunity induced by mucosal immunization. In that regard, it is important to understand the type of helper T lymphocyte response induced by mucosal immunization since the type of helper T lymphocyte stimulated by an antigen is one of the most important factors for defining which type of immune response will follow. Mosmann and colleagues (Cherwinski et al., 1987, *Journal of Experimental Medicine* 166:1229-1244; Mosmann and Coffman, 1989, *Annual Reviews of Immunology* 7:145-173) discovered that there are at least two different types of helper T lymphocytes (Th) which can be identified based on cytokine secretion. Th1 lymphocytes secrete substantial amounts of IL-2 and INF-gamma and execute cell-mediated immune responses (e.g., delayed type hypersensitivity and macrophage activation), whereas Th2 lymphocytes secrete IL-4, IL-5, IL-6 and IL-10 and assist in antibody production for humoral immunity. Theoretically then, antigenic stimulation of one T helper cell subset and not the other would result in production of a particular set of cytokines which would define the resulting immune response.

The presence of IL-2 and INF-gamma coupled with an antigenic stimulus presented by macrophages in the context of Class II MHC molecules can initiate Th1 type responses. The ability of Th1 cells to secrete IL-2 and INF-gamma further amplifies the response by activating Th1 cells in an autocrine fashion and macrophages in a paracrine fashion. These activated leukocytes can release additional cytokines (e.g., IL-6) which may induce the proliferation and

differentiation of antigen specific B lymphocytes to secrete antibody (the effector phase). In this scenario, the predominant isotype secreted by murine B lymphocytes is often IgG2a. In a second scenario (Urban et al., 1992, *Immunol Rev* 5 127:205-220), antigens such as allergens or parasites can effectively stimulate a Th2 lymphocyte response (the inductive phase). Presentation of such antigens to Th2 cells can result in the production of the lymphokines IL-4 and IL-5 which can induce antigen specific B lymphocytes to secrete IgE and IgG1 or induce eosinophillia, respectively (the 10 effector phase). Furthermore, stimulated Th2 cells can secrete IL-10 which has the ability to specifically inhibit secretion of IL-2 and INF-gamma by Th1 lymphocytes and also to inhibit macrophage function.

While these representations are simplistic, it is 15 obvious that the type of T helper cell stimulated affects the resultant cellular immune response as well as the predominant immunoglobulin isotype secreted. Specifically, IL-4 stimulates switching to the IgE and IgG1 isotypes whereas INF-gamma stimulates IgG2a secretion. Numerous studies, 20 predominantly conducted in vitro, have suggested that IL-5, IL-6 and TGF-beta (Th3) can cause isotype switching to IgA.

### 2.1. MUCOSAL ADJUVANTS

Mucosally administered antigens are frequently not immunogenic. A number of strategies have been developed to 25 facilitate mucosal immunization, including the use of attenuated mutants of bacteria (e.g., *Salmonella spp.*) as carriers of heterologous antigens, encapsulation of antigens into microspheres, gelatin capsules, different formulations of liposomes, adsorption onto nanoparticles, use of 30 lipophilic immune stimulating complexes, and addition of bacterial products with known adjuvant properties. The two bacterial products with the greatest potential to function as

mucosal adjuvants are cholera toxin (CT), produced by various strains of *Vibrio cholerae*, and the heat-labile enterotoxin (LT) produced by some enterotoxigenic strains of *Escherichia coli* (Clements et al., 1988, *Vaccine* 6:269-277; Elson, 1989, *Immunology Today* 146:29-33; Lycke et al., 1992, *European Journal of Immunology* 22:2277-2281; Xu-Amano et al., 1993, *Journal of Experimental Medicine* 178:1309-1320; Yamamoto et al., 1996, *Annals of the New York Academy of Sciences* 778:64-71).

10           Although LT and CT have many features in common, these are clearly distinct molecules with biochemical and immunologic differences which make them unique (see below). Both LT and CT are synthesized as multisubunit toxins with A and B components. On thiol reduction, the A component dissociates into two smaller polypeptide chains. One of  
15   these, the A1 piece, catalyzes the ADP-ribosylation of the stimulatory GTP-binding protein (GSa) in the adenylate cyclase enzyme complex on the basolateral surface of the epithelial cell resulting in increasing intracellular levels of cAMP. The resulting increase in cAMP causes secretion of  
20   water and electrolytes into the small intestine through interaction with two cAMP-sensitive ion transport mechanisms involving 1) NaCl cotransport across the brush border of villous epithelial cells, and 2) electrogenic Na dependent Cl secretion by crypt cells (Field, 1980, *Secretory Diarrhea*  
25   pp21-30). The B-subunit binds to the host cell membrane receptor (ganglioside GM1) and facilitates the translocation of the A-subunit through the cell membrane.

Recent studies have examined the potential of CT and LT as a mucosal adjuvant against a variety of bacterial and viral pathogens using whole killed organisms or purified  
30   subunits of relevant virulence determinants from these organisms. Representative examples include tetanus toxoid (Xu-Amano et al., 1993, *Journal of Experimental Medicine*

178:1309-1320; Yamamoto et al., 1996, *Annals of the New York Academy of Sciences* 778:64-71; Xu-Amano et al., 1994, *Vaccine* 12:903-911), inactivated influenza virus (Hashigucci et al., 1996, *Vaccine* 14:113-119; Katz et al., 1996, *Options for the control of influenza. III.*, pp292-297; Katz et al., 1997, *Journal of Infectious Diseases* 175:352-363), recombinant urease from *Helicobacter* spp. (Lee et al., 1995, *Journal of Infectious Diseases* 172:161-171; Weltzin et al., 1997, *Vaccine* 4:370-376), pneumococcal surface protein A from *Streptococcus pneumoniae* (Wu et al., 1997, *Journal of Infectious Diseases* 175:839-846), Norwalk virus capsid protein, synthetic peptides from measles virus (Hathaway et al., 1995, *Vaccine* 13:1495-1500), and the HIV-1 C4/V3 peptide T1SP10 MN(A) (Staats et al., 1996, *Journal of Immunology* 157:462-472). There are many other examples and it is clear that both LT and CT have significant potential for use as adjuvants for mucosally administered antigens (see Dickinson and Clements, 1996, *Mucosal Vaccines* pp73-87 for a recent review). This raises the possibility of an effective immunization program against a variety of pathogens involving the mucosal administration of killed or attenuated agents or relevant virulence determinants of specific agents in conjunction with LT or CT. However, the fact that these "toxins" can stimulate a net luminal secretory response may prevent their use. For instance, as little as 5  $\mu$ g of purified CT was sufficient to induce significant diarrhea in volunteers while 25  $\mu$ g was shown to elicit a full 20-liter cholera purge (Levine et al., 1983, *Microbiological Reviews* 47:510-550). In recently conducted volunteer studies with LT administered alone or in conjunction with the *V. cholerae* Whole Cell/B-Subunit Vaccine, LT was shown to induce fluid secretion at doses as low as 2.5  $\mu$ g when administered in conjunction with the vaccine, while 25  $\mu$ g of LT elicited up to 6-liters of fluid. While the adjuvant effective dose in



humans for either of these toxins has not been established, experiments in animals suggest that it may be comparable to the toxic dose. Taken together, these studies indicate that while LT and CT may be attractive as mucosal adjuvants, studies in animals do not reflect the full toxic potential of these molecules in humans, and that toxicity will seriously limit their practical use for humans.

A number of attempts have been made to alter the toxicity of LT and CT, most of which have focused on eliminating enzymatic activity of the A-subunit associated with enterotoxicity. The majority of these efforts have involved the use of site-directed mutagenesis to change amino acids associated with the crevice where NAD binding and catalysis is thought to occur. Recently, a model for NAD binding and catalysis was proposed (Domenighini et al., 1994, *Molecular Microbiology* 14:41-50; Pizza et al., 1994, *Molecular Microbiology* 14:51-60) based on computer analysis of the crystallographic structure of LT (Sixma et al., 1991, *Nature* (London) 351:371-377; Sixma et al., 1993, *Journal of Molecular Biology* 230:890-918). Replacement of any amino acid in CT or LT involved in NAD-binding and catalysis by site-directed mutagenesis has been shown to alter ADP-ribosyltransferase activity with a corresponding loss of toxicity in a variety of biological assay systems (Lycke et al., 1992, *European Journal of Immunology* 22:2277-2281; Burnette et al., 1991, *Infection and Immunity* 59:4266-4270; Harford et al., 1989, *European Journal of Biochemistry* 183:311-316; Häse et al., 1994, *Infection and Immunity* 62:3051-3057; Lobet et al., 1991, *Infection and Immunity* 59:2870-2879; Merritt et al., 1995, *Nature Structural Biology* 2:269-272; Moss et al., 1993, *Journal of Biological Chemistry* 268:6383-6387; Tsuji et al., 1991, *FEBS Letters* 291:319-321; Tsuji et al., 1990, *Journal of Biological Chemistry* 265:22520-22525). In addition, it has been shown that

exchanging K for E112 in LT not only removes ADP-ribosylating enzymatic activity, but cAMP activation and adjuvant activity as well (Lycke et al., 1992, *European Journal of Immunology* 22:2277-2281). A logical conclusion from the Lycke et al. studies was that ADP-ribosylation and induction of cAMP are essential for the adjuvant activity of these molecules. As a result, a causal linkage was established between adjuvanticity and enterotoxicity. That is, the accumulation of cAMP responsible for net ion and fluid secretion into the gut lumen was thought to be a requisite to adjuvanticity. Recent studies by a number of laboratories have challenged that linkage.

Dickinson and Clements (Dickinson and Clements, 1995, *Infection and Immunity* 63:1617-1623) (Clements et al.) explored an alternate approach to dissociation of enterotoxicity from adjuvanticity. LT requires proteolysis of a trypsin sensitive bond to become fully active. In this enterotoxin, that trypsin sensitive peptide is subtended by a disulfide interchange that joins the A1 and A2 pieces of the A-subunit. In theory, if the A1 and A2 pieces cannot separate, A1 will not be able to find its target (adenylate cyclase) on the basolateral surface or assume the conformation necessary to bind or hydrolyze NAD.

The mutant of Clements et al. has been described more fully in PCT Publication WO96/06627, incorporated herein by reference. The mutant LT holotoxin, designated LT(R192G), was constructed using site-directed mutagenesis to create a single amino acid substitution within the disulfide subtended region of the A-subunit separating A1 from A2. This single amino acid change altered the proteolytically sensitive site within this region, rendering the mutant insensitive to trypsin activation. The physical characteristics of this mutant were examined by SDS-PAGE, its biological activity was examined on mouse Y-1 adrenal tumor cells and Caco-2 cells,

its enzymatic properties determined in an in vitro NAD:agmatine ADP-ribosyltransferase assay, and its immunogenicity and immunomodulating capabilities determined by testing for the retention of immunogenicity and  
5 adjuvanticity.

#### PROPERTIES OF LT(R192G)

- 100 - 1,000 fold less active than cholera toxin or native LT in the mouse Y-1 adrenal cell assay
- Not sensitive to proteolytic activation
- 10 • Does not possess in vitro NAD:agmatine ADP-ribosyltransferase activity
- Does not increase production of cAMP in cultured Caco-2 cells
- Reduced enterotoxicity in the patent mouse intestinal challenge model when compared to native  
15 LT
- Promotes the development of both humoral (antibody) and cell-mediated immune responses against co-administered antigens of a pathogenic microorganism in both the systemic and mucosal compartments
- 20 • Functions as an effective adjuvant when administered mucosally (*i.e.*, orally, intranasally) or parenterally (*i.e.*, subcutaneously)
- Lacks enterotoxicity in humans at adjuvant-effective doses

25 WO 96/06627 describes plasmid pBD95 which can be used to obtain the mutant LT(R192G). Although not described in WO 96/06627, it has recently been discovered that when plasmid pBD95 is used to produce the mutant holotoxin, LT(R192G), by expressing pBD95 in *E. coli*, varying amounts of  
30 free B-subunit can also be recovered as well as the holotoxin. This phenomenon is well known to those of skill in the art since some excess B-subunit is always present following

purification of LT or CT by galactose affinity chromatography. Pizza et al. (Pizza et al., 1994, *Molecular Microbiology* 14:51-61) report mutant and wild-type AB5/AB5+B5 ratios that vary from 40% to 98% depending upon the type of  
5 mutation. Such excess B-subunit can be separated from holotoxin by gel filtration chromatography due to the difference in molecular weight between the holotoxin and the free B-subunit pentamer (84 kd vs. 56 kd).

LT(R192G) has been shown to possess the capability of enhancing an immune response (e.g., IgG, IgA) to antigens  
10 unrelated to LT or LT(R192G). Recent experimental evidence shows that LT(R192G) has utility as an adjuvant for mucosally or parenterally administered antigens; such administration results in the production of serum IgG and/or mucosal sIgA as well as cell-mediated immune responses against the antigen  
15 with which LT(R192G) is delivered and, more importantly, to protect against subsequent challenge with infectious organisms. LT(R192G) has been shown to be an effective mucosal adjuvant and has recently been evaluated in humans in several Phase I safety studies.

20 More recently, Tsuji et al. (Tsuji et al., 1997, *Immunology* 90:176-182) demonstrated that a protease-site deletion mutant LT( $\Delta$ 192-194) also lacks in vitro ADP-ribosylagmatine activity, has a ten-fold reduction in enterotoxicity in rabbit ligated ileal loops, and a 50%  
25 reduction and delayed onset of cAMP induction in cultured myeloma cells. LT( $\Delta$ 192-194) was shown to have increased adjuvant activity for induction of serum IgG and mucosal IgA against measles virus when compared to native LT, LT-B, or LT(E112K). LT( $\Delta$ 192-194) was effective when administered intranasally, subcutaneously, intraperitoneally, or orally  
30 although mucosal IgA responses were only demonstrated following mucosal administration. These investigators also demonstrated increased adjuvant activity for mucosally

administered LT( $\Delta$ 192-194) in conjunction with KLH, BCG, and Ova. These findings are consistent with the findings with LT(R192G). Komase et al. (Komase et al., 1998, *Vaccine* 16(2/3):248-254) shows inclusion of free B-subunit with a mutant LT, in which the Arg at position 7 was changed to Lys, allows less mutant LT to be used for intranasal immunization.

Citation or identification of any reference in Section 2 or any section of this application shall not be construed as an admission that such reference is available as prior art to the present invention.

### 3. SUMMARY OF THE INVENTION

The present invention provides an advantageously easily reproducible means of obtaining pure LT(R192G) free from excess B-subunit of LT, by providing a novel plasmid which expresses LT(R192G) free of excess B-subunit.

The present invention also provides for an expressable DNA encoding both a mutant A-subunit, which has arginine at position 192 changed to glycine, and a wild-type B-subunit, which plasmid allows for the expression of LT(R192G) holotoxin with less than 10% excess B-subunit.

It has been observed by that an excess amount of free B-subunit of the heat-labile enterotoxin of *E. coli* (LT-B) is able to enhance the adjuvanticity of LT(R192G). In addition, free B-subunit in combination with LT(R192G) was found to qualitatively enhance the immunological outcome when LT(R192G) was used as an oral adjuvant. See U.S. Patent Application Serial No. 09/040,990, filed concurrently.

The present invention provides a method for producing pure LT(R192G), substantially free from excess B-subunit. This can allow for subsequent formulation of adjuvant compositions comprised of a controlled,

reproduceable ratio of LT(R192G) to added free B-subunit which are advantageously useful to induce an immune response.

#### 4. DEFINITIONS

5           As used herein, the term "holotoxin" refers to a complex of five B-subunits and one A-subunit of heat-labile enterotoxin.

          As used herein, the term "free B-subunit" refers to the B-subunit of heat-labile enterotoxin substantially free from the A-subunit of heat-labile enterotoxin.

10           As used herein, the term "excess B-subunit" refers to an amount of B-subunit which results in greater than a 5:1 ratio of B-subunits to A-subunit, 5:1 being the ratio of B:A subunits present in native heat-labile enterotoxin holotoxin.

          As used herein, the term "qualitatively enhanced"  
15 refers to an immune response which differs from the type of response elicited by adjuvant and immunogen without excess B-subunit. For example, when administered orally, immunogen with LT(R192G) with excess B-subunit elicits an enhanced T-cell response as compared to immunogen and LT(R192G) without  
20 excess B-subunit, which elicits a mostly humoral response.

          As used herein, the term "quantitatively enhanced" refers to an immune response which is greater than normal, but does not differ in the type of immune response elicited. In one embodiment, adjuvanticity of LT(R192G) is enhanced  
25 four fold, such that only one fourth the amount of LT(R192G) with excess B-subunit is required, as compared to LT(R192G) without excess B-subunit, to elicit a comparable immune response.

#### 5. BRIEF DESCRIPTION OF THE FIGURES

30           The present invention may be understood more fully by reference to the following detailed description of the

invention, examples of specific embodiments of the invention and the appended figures in which:

Figure 1 is a schematic diagram of plasmid pCS95, which encodes both subunits LT A and B under the control of the *lac* promoter. Figure 1A illustrates the construction of plasmid pCS95 which contains the nucleotide sequence encoding mutant LT(R192G). Plasmid pCS95 was constructed by replacing the BamHI-XbaI of pBD95 with the BamHI-XbaI fragment of pDF82. Figure 1B shows the single amino acid change in LT(R192G). Plasmid pCS95 provides LT(R192G) which contains the single base substitution at amino acid residue 192 of subunit A, coding for Gly rather than Arg, which preserves the reading frame but eliminates the proteolytic site.

Figure 2 is a graphic illustration of the effect of various ratios of free B-subunit to LT(R192G) in the patent mouse intestinal assay. For these studies, LT(R192G) with no excess B-subunit was admixed with different ratios of B-subunit and examined for enterotoxicity in the patent mouse assay. Groups of mice were orally inoculated with native LT at 5, 25, 50 or 100  $\mu$ g, or with 25  $\mu$ g of LT(R192G) admixed with a different amount of free B-subunit. Following a three hour interval, the gut:carcass ratio of each animal was determined. The gut-carcass ratio is defined as the intestinal weight divided by the remaining carcass weight. There were three animals per group and the means for each data point are shown.

Figure 3 is an additional graphic illustration of the effect of excess B-subunit in the patent mouse intestinal assay. For these studies, groups of mice were orally inoculated with native LT at 5, 25, or 125  $\mu$ g, or with 25  $\mu$ g of LT(R192G). Other groups received either 25  $\mu$ g of native LT or 25  $\mu$ g of LT(R192G) admixed with a 3:1 or 10:1 excess of free B-subunit. Following a three hour interval, the gut:carcass ratio of each animal was determined. There were

three animals per group and the means for each data point are shown.

Figure 4 is a graphic illustration of the effect of excess B-subunit on the ability of LT(R192G) to function as an immunologic adjuvant for induction of serum IgG when administered intranasally. Mice were immunized intranasally with Ovalbumin (Ova) alone or in conjunction with 5  $\mu$ g of LT(R192G) or 1.25  $\mu$ g of LT(R192G) plus 3.75  $\mu$ g of excess free B-subunit, designated 1AB5:3B5. Serum anti-Ova IgG was determined by ELISA. There were seven animals per group and the means for each data point are shown.

Figure 5 is a graphical illustration of the effect of excess B-subunit on the ability of LT(R192G) to function as an immunologic adjuvant for production of antigen-specific Th1-type cytokines, specifically, IFN-gamma, by mononuclear cells from the spleens of animals immunized intranasally. Mice were immunized intranasally with Ovalbumin (Ova) alone or in conjunction with 5  $\mu$ g of LT(R192G) or 1.25  $\mu$ g of LT(R192G) plus 3.75  $\mu$ g of excess free B-subunit, designated 1AB5:3B5. Cytokines were determined by ELISA following a T-cell restimulation assay.

Figure 6 is a graphic illustration of the effect of excess B-subunit on the ability of LT(R192G) to function as an immunologic adjuvant for production of antigen-specific Th2-type cytokines, specifically, IL-10, by mononuclear cells from the spleens of animals immunized intranasally. Mice were immunized intranasally with Ovalbumin (Ova) alone or in conjunction with 5  $\mu$ g of LT(R192G) or 1.25  $\mu$ g of LT(R192G) plus 3.75  $\mu$ g of excess free B-subunit, designated 1AB5:3B5. Cytokines were determined by ELISA following a T-cell restimulation assay.

Figure 7 is a graphical demonstration that excess B-subunit enhances the ability of LT(R192G) to function as an immunologic adjuvant for induction of serum IgG when



administered orally. Mice were immunized orally with a purified bacterial protein, Colonizing Factor I (CFAI) from enterotoxigenic *E. coli*, in conjunction with 6.25  $\mu\text{g}$  of LT(R192G) or 6.25  $\mu\text{g}$  of LT(R192G) plus 18.75  $\mu\text{g}$  of free B-subunit, designated 1AB5:3B5. Serum anti-CFAI IgG was determined by ELISA. There were seven animals per group and the means for each data point are shown.

Figure 8 is an additional graphic illustration that excess B-subunit enhances the ability of LT(R192G) to function as an immunologic adjuvant for induction of serum IgG when administered orally. Mice were immunized orally with Ovalbumin (Ova) alone or in conjunction with 25  $\mu\text{g}$  of LT(R192G) or 6.25  $\mu\text{g}$  of LT(R192G) plus 18.75  $\mu\text{g}$  of free B-subunit, designated 1AB5:3B5. Serum anti-Ova IgG was determined by ELISA. There were ten animals per group and the means for each data point are shown.

Figure 9 is a graphic demonstration that excess B-subunit enhances the ability of LT(R192G) to function as an immunologic adjuvant for production of antigen-specific Th1-type cytokines, specifically, IFN-gamma, by mononuclear cells from the spleens of animals immunized orally. Mice were immunized orally with Ovalbumin (Ova) alone or in conjunction with 25  $\mu\text{g}$  of LT(R192G) or 6.25  $\mu\text{g}$  of LT(R192G) plus 18.75  $\mu\text{g}$  of free B-subunit, designated 1AB5:3B5. Cytokines were determined by ELISA following a T-cell restimulation assay.

Figure 10 is a graphic demonstration that excess B-subunit enhances the ability of LT(R192G) to function as an immunologic adjuvant for production of antigen-specific Th2-type cytokines, specifically, IL-10, by mononuclear cells from the spleens of animals immunized orally. Mice were immunized orally with Ovalbumin (Ova) alone or in conjunction with 25  $\mu\text{g}$  of LT(R192G) or 6.25  $\mu\text{g}$  of LT(R192G) plus 18.75  $\mu\text{g}$

of free B-subunit, designated 1AB5:3B5. Cytokines were determined by ELISA following a T-cell restimulation assay.

## 6. DETAILED DESCRIPTION OF THE INVENTION

5 The present invention provides pure LT(R192G) by providing novel compositions of LT(R192G) and methods of using said compositions as adjuvants.

The present invention also provides for an expressable DNA encoding both a mutant A-subunit, which has arginine at position 192 changed to glycine, and a wild-type  
10 B-subunit, which plasmid allows for the expression of LT(R192G) holotoxin with less than 10% excess B-subunit.

LT is a member of the ADP-ribosylating family of bacterial toxins and, like other bacterial toxins that are members of the A-B toxin family, requires proteolysis of a  
15 trypsin sensitive bond to become fully active. That trypsin sensitive peptide is subtended by a disulfide interchange that joins the A1 and A2 pieces of the A-subunit. In theory, if the A1 and A2 pieces cannot separate, A1 will not be able to find its target (adenylate cyclase) on the basolateral  
20 surface or assume the conformation necessary to bind or hydrolyze NAD. An unexpected finding was that LT(R192G) has greatly reduced toxicity, but retains the adjuvant properties of wild type LT.

### 6.1. PRODUCTION OF LT(R192G)

25 LT(R192G) can be produced by a number of means apparent to those of skill in the art. For example, LT(R192G) can be isolated from *E. coli* expressing pBD95, a plasmid fully described in PCT Publication WO96/06627. Subsequent to the effective priority date of WO96/06627,  
30 others have had success in isolating LT(R192G) from *E. coli* expressing other plasmid constructs. (Grant et al., (1994), *Infection and Immunity* 62(10):4270-4278). Plasmid pCS95,

fully described in Example 6.1 can also be utilized to produce isolated or substantially pure LT(R192G) in *E. coli*.

LT(R192G) can be isolated by agarose affinity chromatography from bacteria expressing an LT(R192G) encoding  
5 plasmid. Alternate methods of purification will be apparent to those skilled in the art.

LT(R192G) produced by any means can be further purified by gel filtration chromatography, which allows for the separation of holotoxin from any free A or B subunits.

10

### 6.2. COMPOSITIONS OF LT(R192G)

The present invention provides mutant LT(R192G) useful for compositions and methods to promote the production of serum and/or mucosal antibodies as well as cell-mediated  
immune responses against an antigen that is simultaneously  
15 administered with a genetically modified bacterial toxin, i.e., LT(R192G).

Compositions of the present invention are useful for the formulation of adjuvant compositions through the mixing of a substantially pure preparation of LT(R192G), free  
20 LT-B subunit, and an antigen.

### 6.3. MODE OF ADMINISTRATION OF LT(R192G) AND UNRELATED ANTIGENS

The product of this invention is useful to prepare formulations which can be administered as described below.  
25

LT(R192G) in combination with B-subunit free of holotoxin at any B-subunit to LT(R192G) ratio of 1:1 or greater is administered in conjunction with any biologically relevant antigen and/or vaccine, such that an increased  
immune response to said antigen and/or vaccine is achieved.

30 LT(R192G) plus free B-subunit and antigen are administered simultaneously in a pharmaceutical composition

comprising an effective amount of LT(R192G) plus free B-subunit and an effective amount of antigen.

The antigen, the LT(R192G), and the free B-subunit free of holotoxin are administered separately within a short time of each other.

The antigen is administered separately within a short time of the simultaneous administration of the LT(R192G) and the B-subunit free of holotoxin.

The LT(R192G) administered in combination with free B-subunit is at a ratio of between 1:1 and 100:1 of B-subunit to LT(R192G). LT(R192G) administered in combination with free B-subunit can be at a weight ratio of 2:1 to 10:1 of B-subunit to LT(R192G). The LT(R192G) administered in combination with free B-subunit can be at a weight ratio of about 3:1 of B-subunit to LT(R192G).

The mode of administration is mucosal (i.e., intranasal, oral, rectal) or parenteral (i.e., subcutaneous, intramuscular, intradermal, intravenous, intraperitoneal). The respective amounts of LT(R192G) plus free B-subunit and antigen will vary depending upon the identity of the route of administration, antigen employed and the species of animal to be immunized. The initial administration of LT(R192G) plus free B-subunit and antigen can be followed by a boost of the relevant antigen. Alternatively, no boost is given. The timing of boosting may vary, depending on the route, antigen and the species being treated. The modifications in route, dosage range and timing of boosting for any given species and antigen are readily determinable by routine experimentation. The boost may be of antigen alone or in combination with LT(R192G) plus free B-subunit.

30

#### 6.4. ANTIGENS

The methods and compositions of the present invention are intended for use both in immature and mature

vertebrates, in particular birds, mammals, and humans. Useful antigens, as examples and not by way of limitation, include antigens from pathogenic strains of bacteria (*Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Neisseria gonorrhoea*,  
5 *Neisseria meningitidis*, *Corynebacterium diphtheriae*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium tetani*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella ozaenae*, *Klebsiella rhinoscleromatis*, *Staphylococcus aureus*, *Vibrio cholerae*, *Escherichia coli*,  
10 *Pseudomonas aeruginosa*, *Campylobacter jejuni*, *Aeromonas hydrophila*, *Bacillus cereus*, *Edwardsiella tarda*, *Yersinia enterocolitica*, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Salmonella typhimurium*, *Treponema pallidum*, *Treponema*  
15 *pertenue*, *Treponema caratenum*, *Borrelia vincentii*, *Borrelia burgdorferi*, *Leptospira icterohemorrhagiae*, *Mycobacterium tuberculosis*, *Toxoplasma gondii*, *Pneumocystis carinii*, *Francisella tularensis*, *Brucella abortus*, *Brucella suis*, *Brucella melitensis*, *Mycoplasma* spp., *Rickettsia prowazeki*, *Rickettsia tsutsugumushi*, *Chlamydia* spp., *Helicobacter*  
20 *pylori*); pathogenic fungi (*Coccidioides immitis*, *Aspergillus fumigatus*, *Candida albicans*, *Blastomyces dermatitidis*, *Cryptococcus neoformans*, *Histoplasma capsulatum*); protozoa (*Entamoeba histolytica*, *Trichomonas tenax*, *Trichomonas*  
25 *hominis*, *Trichomonas vaginalis*, *Trypanosoma gambiense*, *Trypanosoma rhodesiense*, *Trypanosoma cruzi*, *Leishmania donovani*, *Leishmania tropica*, *Leishmania braziliensis*, *Pneumocystis pneumonia*, *Plasmodium vivax*, *Plasmodium*  
*falciparum*, *Plasmodium malariae*); or Helminths (*Enterobius vermicularis*, *Trichuris trichiura*, *Ascaris lumbricoides*,  
30 *Trichinella spiralis*, *Strongyloides stercoralis*, *Schistosoma japonicum*, *Schistosoma mansoni*, *Schistosoma haematobium*, and hookworms) either presented to the immune system in whole

cell form or in part isolated from media cultures designed to grow said organisms which are well know in the art, or protective antigens from said organisms obtained by genetic engineering techniques or by chemical synthesis.

5           Other relevant antigens include pathogenic viruses (as examples and not by limitation: Poxviridae, Herpesviridae, Herpes Simplex virus 1, Herpes Simplex virus 2, Adenoviridae, Papovaviridae, Enteroviridae, Picornaviridae, Parvoviridae, Reoviridae, Retroviridae, influenza viruses, parainfluenza viruses, mumps, measles, 10 respiratory syncytial virus, rubella, Arboviridae, Rhabdoviridae, Arenaviridae, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis E virus, Non-A/Non-B Hepatitis virus, Rhinoviridae, Coronaviridae, Rotoviridae, and Human Immunodeficiency Virus) either presented to the 15 immune system in whole or in part isolated from media cultures designed to grow such viruses which are well known in the art or protective antigens therefrom obtained by genetic engineering techniques or by chemical synthesis.

          Further examples of relevant antigens include, but 20 are not limited to, vaccines. Examples of such vaccines include, but are not limited to, influenza vaccine, pertussis vaccine, diphtheria and tetanus toxoid combined with pertussis vaccine, hepatitis A vaccine, hepatitis B vaccine, hepatitis C vaccine, hepatitis E vaccine, Japanese 25 encephalitis vaccine, herpes vaccine, measles vaccine, rubella vaccine, mumps vaccine, mixed vaccine of measles, mumps and rubella, papillomavirus vaccine, parvovirus vaccine, respiratory syncytial virus vaccine, Lyme disease vaccine, polio vaccine, varicella vaccine, gonorrhea vaccine, schistosomiasis vaccine, rotavirus vaccine, mycoplasma 30 vaccine pneumococcal vaccine, meningococcal vaccine, campylobacter vaccine, helicobacter vaccine, cholera vaccine, enterotoxigenic *E. coli* vaccine, enterohemorrhagic *E. coli*

vaccine, shigella vaccine, salmonella vaccine and others. These can be produced by known common processes. In general, such vaccines comprise either the entire organism or virus grown and isolated by techniques well known to the skilled  
5 artisan or comprise relevant antigens of these organisms or viruses which are produced by genetic engineering techniques or chemical synthesis. Their production is illustrated by, but not limited to, the following:

Influenza vaccine: a vaccine comprising the whole  
10 or part of hemagglutinin, neuraminidase, nucleoprotein and matrix protein which are obtainable by purifying a virus, which is grown in embryonated eggs, with ether and detergent, or by genetic engineering techniques or chemical synthesis.

Pertussis vaccine: a vaccine comprising the whole  
15 or a part of pertussis toxin, hemagglutinin and K-agglutinin which are obtained from avirulent toxin with formalin which is extracted by salting-out or ultracentrifugation from the culture broth or bacterial cells of Bordetella pertussis, or by genetic engineering techniques or chemical synthesis.

Diphtheria and tetanus toxoid combined with  
20 pertussis vaccine: a vaccine mixed with pertussis vaccine, diphtheria and tetanus toxoid.

Japanese encephalitis vaccine: a vaccine  
comprising the whole or part of an antigenic protein which is obtained by culturing a virus intracerebrally in mice and purifying the virus particles by centrifugation or ethyl  
25 alcohol and inactivating the same, or by genetic engineering techniques or chemical synthesis.

Hepatitis B vaccine: a vaccine comprising the  
whole or part of an antigen protein which is obtained by isolating and purifying the HBs antigen by salting-out or  
30 ultracentrifugation, obtained from hepatitis carrying blood, or by genetic engineering techniques or by chemical synthesis.

Measles vaccine: a vaccine comprising the whole or part of a virus grown in a cultured chick embryo cells or embryonated egg, or a protective antigen obtained by genetic engineering or chemical synthesis.

5 Rubella vaccine: a vaccine comprising the whole or part of a virus grown in cultured chick embryo cells or embryonated egg, or a protective antigen obtained by genetic engineering techniques or chemical synthesis.

10 Mumps vaccine: a vaccine comprising the whole or part of a virus grown in cultured rabbit cells or embryonated egg, or a protective antigen obtained by genetic engineering techniques or chemical synthesis.

Mixed vaccine of measles, rubella and mumps: a vaccine produced by mixing measles, rubella and mumps vaccines.

15 Rotavirus vaccine: a vaccine comprising the whole or part of a virus grown in cultured MA 104 cells or isolated from the patient's feces, or a protective antigen obtained by genetic engineering techniques or chemical synthesis.

20 Mycoplasma vaccine: a vaccine comprising the whole or part of mycoplasma cells grown in a liquid culture medium for mycoplasma or a protective antigen obtained by genetic engineering techniques or chemical synthesis.

Those conditions for which effective prevention may be achieved by the present method will be obvious to the skilled artisan.

25 The vaccine preparation compositions of the present invention can be prepared by mixing the above illustrated antigens and/or vaccines with LT(R192G) at a desired ratio. Pyrogens or allergens should naturally be removed as completely as possible. The antigen preparation of the  
30 present invention can be used by preparing the antigen per se and the LT(R192G) separately or together.



Further, the present invention encompasses a kit comprising an effective amount of antigen and an adjuvant effective amount of LT(R192G). In use, the components of the kit can either first be mixed together and then administered  
5 or the components can be administered separately within a short time of each other.

The vaccine preparation compositions of the present invention can be combined with either a liquid or solid pharmaceutical carrier, and the compositions can be in the form of tablets, capsules, powders, granules, suspensions or  
10 solutions. The compositions can also contain suitable preservatives, coloring and flavoring agents, or agents that produce slow release. Potential carriers that can be used in the preparation of the pharmaceutical compositions of this invention include, but are not limited to, gelatin capsules,  
15 sugars, cellulose derivations such as sodium carboxymethyl cellulose, gelatin, talc, magnesium stearate, vegetable oil such as peanut oil, etc., glycerin, sorbitol, agar and water. Carriers may also serve as a binder to facilitate tableting of the compositions for convenient administration.

20

## 7. EXAMPLES

The following examples are presented for purposes of illustration only and are not intended to limit the scope of the invention in any way.

25

30

### 7.1. EXAMPLE: PRODUCTION OF LT(R192G)

The wild-type LT toxin is encoded on a naturally occurring plasmid found in strains of enterotoxigenic *E. coli* capable of producing this toxin. Clements et al. had previously cloned the LT gene from a human isolate of *E. coli* designated H10407. This subclone consists of a 5.2 kb DNA fragment from the enterotoxin plasmid of H10407 inserted into the *Pst*I site of plasmid pBR322 (Clements et al, 1983, *Infect. Immun.* 40:653). This recombinant plasmid, designated pDF82, has been extensively characterized and expresses LT under control of the native LT promoter. From pDF82, Clements et al. derived plasmid pBD95, which is fully described in PCT Publication WO96/06627.

Figure 1A shows the construction of plasmid pCS95, which was constructed by inserting the native LT-A subunit regulatory region upstream from the LT-A coding region of pBD95. Figure 1B shows the Arg to Gly mutation at position 192. The BamHI and XbaI restriction sites referred to in the diagram as "new" were added by site directed mutagenesis, as described in PCT Publication WO96/06627. The new XbaI site was added through a silent mutation, resulting in no alteration of the amino acid sequence of the peptide encoded by the gene.

LT(R192G) was then purified by agarose affinity chromatography from bacteria expressing pCS95. This mutant LT, designated LT(R192G) was then examined by SDS-polyacrylamide gel electrophoresis for modification of the trypsin sensitive bond. Samples were examined with and without exposure to trypsin and compared with native (unmodified) LT. LT(R192G) does not dissociate into A<sub>1</sub> and A<sub>2</sub> when incubated with trypsin, thereby indicating that sensitivity to protease has been removed.

7.2. **EXAMPLE: LT(R192G) AND FREE B-SUBUNIT  
IN THE PATENT MOUSE ENTEROTOXICITY ASSAY**

LT(R192G) with no free B-subunit was admixed with  
different ratios of B-subunit and examined for toxicity in  
the patent mouse assay. As shown in Figure 2, the addition  
of excess free B-subunit to LT(R192G) results in a reduction  
of the gut/carcass ratio as measured in the patent mouse  
assay. To further evaluate this finding, free B-subunit was  
admixed with LT(R192G) and also with native LT at a ratio of  
either 3:1 or 10:1. As shown in Figure 3, free B-subunit  
suppresses the toxicity of native LT.

7.3. **EFFECT OF FREE B-SUBUNIT ON INTRANASAL ADJUVANTICITY**

The effect of administration of LT(R192G) with  
excess free B-subunit on both intranasal and oral  
adjuvanticity was examined by administration of an  
illustrative antigen with the adjuvant composition to  
different mucosal surfaces.

Ovalbumin (Ova) was selected as a representative  
antigen for these studies. A number of investigations,  
including our own (Clements et al., 1988, *Vaccine* 6:269-277;  
Dickinson and Clements, 1996, *Mucosal Vaccines* \_\_:73-87;  
Dickinson and Clements, 1995, *Infection and Immunity* 63:1617-  
1623; Tsuji et al., 1997, *Immunology* 90:176-182; Yamamoto et  
al., 1997, *Journal of Experimental Medicine* 185:1203-1210;  
Yamamoto et al., 1997, *Proceedings of the National Academy of  
Sciences* 94:5267-5272; DiTommaso et al., 1996, *Infection and  
Immunity* 64:974-979; Douce et al., 1995, *Proceedings of the  
National Academy of Sciences* 92:1644-1648; Douce et al.,  
1997, *Infection and Immunity* 65:2821-2828), have used this  
protein and it provides a useful reference for comparison to  
other studies. For those studies, both serum anti-Ova IgG  
and Ova-specific T-cell responses were examined.

A second antigen, Colonizing Factor Antigen I (CFAI) of enterotoxigenic *E. coli* was included in one set of experiments. In these studies, serum anti-CFAI was examined because anti-CFAI antibodies may be protective against  
5 diarrheal disease caused by these organisms.

In the first series of experiments, mice were immunized intranasally with Ova alone or in conjunction with 5  $\mu$ g of LT(R192G) or 1.25  $\mu$ g of LT(R192G) plus 3.75  $\mu$ g of free B-subunit, designated 1AB5:3B5. Serum anti-Ova IgG was determined by ELISA. There were seven animals per group and  
10 the means for each data point are shown. As shown in Figure 4, mice immunized intranasally with Ova in conjunction with LT(R192G) containing excess B-subunit had serum anti-Ova IgG responses indistinguishable from animals immunized with Ova in conjunction with LT(R192G) without excess of B-subunit,  
15 even though a significantly lower total amount of LT(R192G) was administered (1.25  $\mu$ g vs. 5  $\mu$ g). This demonstrates that excess free B-subunit is able to enhance the adjuvanticity of LT(R192G). When the Ova-specific T-cell responses from these animals were examined, both the Th1/IFN-gamma (Figure 5) and  
20 Th2/IL-10 (Figure 6) anti-Ova responses were equivalent when free B-subunit was included in the adjuvant formulation compared to LT(R192G) without free B-subunit. There is no significant difference in the IFN-gamma and IL-10 responses between these two groups.

25

#### 7.4. EFFECT OF FREE B-SUBUNIT ON ORAL ADJUVANTICITY

In the next series of experiments, mice were immunized orally with purified Colonizing Factor I (CFAI) from enterotoxigenic *E. coli* in conjunction with 6.25  $\mu$ g of LT(R192G) or 6.25  $\mu$ g of LT(R192G) plus 18.75  $\mu$ g of free  
30 B-subunit, designated 1AB5:3B5. Serum anti-CFAI IgG was determined by ELISA. There were seven animals per group and the means for each data point are shown. As shown in Figure

7, mice immunized orally with CFAI in conjunction with LT(R192G) containing excess B-subunit had serum anti-CFAI IgG responses significantly higher than did animals immunized with CFAI in conjunction with LT(R192G) without excess of B-subunit. This demonstrates that excess B-subunit is able to alter the type of immune response elicited by oral administration of LT(R192G) with an antigen. One possibility was that the CFAI response was unique because of the inherent ability of colonizing factors to bind to epithelial cells. To further elucidate this unexpected finding, a third series of experiments was performed.

In this series of experiments, mice were immunized orally with Ova alone or in conjunction with 25  $\mu$ g of LT(R192G) or 6.25  $\mu$ g of LT(R192G) plus 18.75  $\mu$ g of free B-subunit, designated 1AB5:3B5. Serum anti-Ova IgG was determined by ELISA. There were ten animals per group and the means for each data point are shown. As shown in Figure 8, mice immunized orally with Ova in conjunction with LT(R192G) containing excess B-subunit had significantly higher serum anti-Ova IgG responses than did animals immunized with Ova in conjunction with LT(R192G) without excess of B-subunit, even though a significantly lower total amount of LT(R192G) was administered (6.25  $\mu$ g vs. 25  $\mu$ g). This finding was consistent with the increased anti-CFAI serum IgG responses observed when excess B-subunit was included in the oral adjuvant formulation with CFAI as the antigen (Figure 7). When the Ova-specific T-cell responses from these animals were examined, both the Th1/IFN-gamma (Figure 9) and Th2/IL-10 (Figure 10) anti-Ova responses were qualitatively different and quantitatively enhanced when free B-subunit was included in the adjuvant formulation compared to LT(R192G) without free B-subunit.

These findings demonstrate that the presence of free B-subunit elicits an antigen-specific T-cell response, a

response which is substantially non-existent when LT(R192G) is used without excess free B-subunit, when LT(R192G) is used as an oral adjuvant. This represents a qualitative change in the type of immune response elicited. These findings also illustrate that excess free B-subunit enhances the humoral immune response elicited by LT(R192G) when used as an oral adjuvant; this represents a quantitative change in response.


#### 8. DEPOSIT OF MICROORGANISMS

The following microorganism containing the designated plasmid was deposited with the American Type Culture Collection (ATCC), (present address: 1081 University Boulevard, Manassas, VA 20110-2209) on March 13, 1998, and has been assigned the indicated accession number:

| <u>Microorganism</u> | <u>Accession Number</u> |
|----------------------|-------------------------|
| E. coli JM83 (pCS95) | 98696                   |

Although the invention is described in detail with reference to specific embodiments thereof, it will be understood that variations which are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

| MICROORGANISMS   |  |
|--|--|
| Optional Sheet in connection with the microorganism referred to on page <u>28</u> , lines <u>15-16</u> of the description *  |  |
| <b>A. IDENTIFICATION OF DEPOSIT *</b><br>Further deposits are identified on an additional sheet *  |  |
| Name of depositary institution *<br><b>American Type Culture Collection</b>  |  |
| Address of depositary institution (including postal code and country) *<br><b>10801 University Blvd.<br/>Manassas, VA 20110-2209<br/>US</b>                            |  |
| Date of deposit * <b>March 13, 1998</b> Accession Number * <b>98696</b>  |  |
| <b>B. ADDITIONAL INDICATIONS</b> * (leave blank if not applicable). This information is continued on a separate attached sheet   |  |
|  |  |
| <b>C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *</b> (if the indications are not all designated States)  |  |
|  |  |
| <b>D. SEPARATE FURNISHING OF INDICATIONS *</b> (leave blank if not applicable)   |  |
| The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit") |  |
|  |  |
| <b>E.</b> <input checked="" type="checkbox"/> This sheet was received with the International application when filed (to be checked by the receiving Office)            |  |
| <div style="text-align: right;"><br/>(Authorized Officer)</div>                    |  |
| <input type="checkbox"/> The date of receipt (from the applicant) by the International Bureau *  |  |
| was _____  |  |
| <div style="text-align: right;">_____<br/>(Authorized Officer)</div>   |  |

Form PCT/RO/134 (January 1981)

**WHAT IS CLAIMED IS:**

1. A composition comprising an isolated mutant *E. coli* heat-labile enterotoxin holotoxin, in which arginine at amino acid position 192 is replaced with glycine, which  
5 holotoxin has immunologic adjuvant activity and is:

- (a) substantially less toxic than native *E. coli* heat-labile enterotoxin (LT) holotoxin as measured in the Y-1 adrenal cell assay, and
- (b) substantially free from excess free B-subunit of  
10 LT.

2. The composition of claim 1 in which the holotoxin is encoded by plasmid pCS95 having ATCC Accession number XXX, which expresses both subunit A and subunit B of the *E. coli* heat-labile enterotoxin substantially free from  
15 excess B-subunit.

3. A composition comprising an isolated mutant *E. coli* heat-labile enterotoxin holotoxin, in which arginine at amino acid position 192 is replaced with glycine, which  
20 holotoxin has immunologic adjuvant activity and:

- (a) is substantially less toxic than native *E. coli* heat-labile enterotoxin (LT) holotoxin as measured in the Y-1 adrenal cell assay, and
- (b) contains less than 10% free B-subunit of LT.

25

4. A method for obtaining mutant *E. coli* heat-labile enterotoxin holotoxin, in which arginine at amino acid position 192 is replaced with glycine, which holotoxin has immunologic adjuvant activity and is:

- (a) substantially less toxic than native *E. coli* heat-labile enterotoxin (LT) holotoxin as measured in  
30 the Y-1 adrenal cell assay, and



(b) substantially free from excess free B-subunit of  
LT,  
by expressing plasmid pCS95 in *E. coli* and harvesting the  
mutant LT.

5

10

15

20

25

30

1/11




FIG. 1A

2/11




FIG. 1B

3/11





FIG.2

4/11



BEST AVAILABLE COPY

5/11




FIG.4




FIG.5




FIG. 6



8/11




FIG. 7

9/11




FIG.8




FIG. 9




FIG.10

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/05625

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : A61K 39/00, 39/38, 39/02; C12N 15/64

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/184.1, 200.1, 08.1, 234.1, 235.1, 240.1, 241.1, 261.1; 435/91.4, 172.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category* | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|-----------|---|-----------------------|
| Y         | <b>KOMASE et al.</b> Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine. Vaccine, January-February 1998, Vol. 16, No. -3, pages 248-254, see abstract.  | 1-4                   |
| Y, P      | <b>CHONG et al.</b> LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. Vaccine, April 1998, Vol. 16, No. 7, pages 732-740, see entire document. | 1-4                   |

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

|   |  |
|---|--|
| * Special categories of cited documents:  | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| *A* document defining the general state of the art which is not considered to be of particular relevance  | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| *B* earlier document published on or after the international filing date  | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *A* document member of the same patent family  |
| *O* document referring to an oral disclosure, use, exhibition or other means  |  |
| *P* document published prior to the international filing date but later than the priority date claimed  |  |

|   |  |
|---|--|
| Date of the actual completion of the international search<br>07 JUNE 1999   | Date of mailing of the international search report<br>12 JUL 1999                |
| Name and mailing address of the ISA/US<br>Commissioner of Patents and Trademarks<br>Box PCT<br>Washington, D.C. 20231<br>Facsimile No. (703) 305-3230 | Authorized officer<br>S. DEVI <i>[Signature]</i><br>Telephone No. (703) 308-0196 |

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/05625

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|-----------|--|-----------------------|
| Y         | <b>TAMURA et al.</b> Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine, September 1994, Vol. 12, No. 12, pages 1083-1089, see entire abstract.                                       | 1-4                   |
| Y, P      | <b>O'NEAL et al.</b> Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT) and LT-R192G induce protection from rotavirus challenge. Journal of Virology, April 1998, Vol. 72, No. 4, pages 3390-3393, see entire document. | 1-4                   |
| Y         | <b>GRANT et al.</b> Role of trypsin-like cleavage at arginine 192 in the enzymatic and cytotoxic activities of Escherichia coli heat-labile enterotoxin. Infect. Immun. October 1994, Vol. 62, No. 10, pages 4270-4278, see entire document.   | 1-4                   |
| Y         | <b>TSUJI et al.</b> Relationship between a low toxicity of the mutant A subunit of enterotoxigenic Escherichia coli enterotoxin and its strong adjuvant action. Immunology, February 1997, Vol. 90, No. 2, pages 176-182, see entire document.   | 1-4                   |
| Y, P      | <b>FREYTAG et al.</b> Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect. Immun. February 1999, Vol. 67, No. 2, pages 826-833, see abstract.  | 1-4                   |
| Y         | <b>WO 96/06627 A1 (THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND. )</b> 07 March 1996, see entire document.  | 1-4                   |
| A         | <b>WO 92/19265 A1 (AMGEN INC.)</b> 12 November 1992, see entire document.  | 1-4                   |
| A         | <b>SIXMA et al.</b> Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin. J. Biol. Mol. 1993, Vol. 230, pages 890-918, see entire document.  | 1-4                   |
| A         | <b>WO 93/13202 (BIOCINE SCLANO SPA)</b> 08 July 1993, see entire document.   | 1-4                   |
| A         | <b>LYCKE et al.</b> The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. September 1992, Vol. 2, No. 9, pages 277-2281, see entire document.  | 1-4                   |

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/05625

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|-----------|---|-----------------------|
| Y         | <b>OPLINGER et al.</b> G10. Safety and immunogenicity in volunteers of a new candidate oral mucosal adjuvant. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington D.C., 1997, abstract 10, page 193, see entire abstract. | 1-4                   |
| A         | <b>OKAMOTO et al.</b> Effect of substitution of glycine for arginine at position 146 of the A1 subunit on biological activity of Escherichia coli heat-labile enterotoxin. J. Bacteriol. May 1988, Vol. 170, No. 5, pages 2208-2221, see entire document.   | 1-4                   |
| A         | <b>DOUCE et al.</b> Mutants of Escherichia coli heat-labile toxin ADP-ribosyltransferase activity act as non-toxic, mucosal adjuvants. Proc. Nat. Acad. Sci. February 1995, Vol. 92, No. 5, pages 1644-1648, see entire document.   | 1-4                   |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/05625

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/184.1, 200.1, 08.1, 234.1, 235.1, 240.1, 241.1, 261.1; 435/91.4, 172.1

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, MEDLINE, EMBASE, BIOSIS, TOXLINE, AGRICOLA, JAPIO, DERWENT, INSIDE CONFERENCES ,  
CURRENT CONTENTS

Search terms: mutant holotoxin, LT(R192G); pCS95; adjuvant; arginine 192 glycine